Compare iShares MSCI Hong Kong ETF (EWH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: iShares MSCI Hong Kong ETF is far larger — about 29.4× Cassava Sciences Inc's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Cassava Sciences Inc for 37 Days on average.
| EWH | FLNA | |
|---|---|---|
Market Cap | $1.16B | $39.40M |
Volume | 3,176,523 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $4.64 |
52-Week Low | $20.66 | $0.68 |
Typical Hold Time | 61 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Empowered Funds reducing its position by 70.2% in August 2026.
The outlook remains cautious given Hong Kong market volatility and geopolitical risks. Investment opportunity exists for contrarian investors if technical oversold conditions lead to rebound, but risks include continued Hang Seng weakness and macroeconomic pressures. Wall Street sentiment appears mixed with some seeing value while others reduce exposure.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
